Biogen may get boost from hemophilia drug data

02/10/2013 | American City Business Journals

Recent data from a late-stage study showed promising results for Biogen Idec's two hemophilia drugs, Factor VIII and Factor IX, and FDA approval could mean more jobs at the company. Biogen has filed a regulatory review of Factor IX and is planning to file for Factor VIII in the first half of the year.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL